NASDAQ$ROIV
Roivant Sciences Ltd · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Roivant Sciences reported its Q4 2023 financial results and provided a business update.
Roivant Sciences reported VTAMA net product revenue of $13.7 million for the quarter ended March 31, 2023, with a 25% gross-to-net yield. The company's cash, cash equivalents, and restricted cash stood at $1.7 billion as of March 31, 2023.
- RVT-3101 demonstrated improved efficacy in the TUSCANY-2 Phase 2b study for ulcerative colitis.
- A Phase 2 study of RVT-3101 in Crohn's disease has been initiated, with topline data expected in Q4 of calendar year 2024.
- VTAMA net product revenue was $13.7M for the quarter and $28.0M for the fiscal year ended March 31, 2023.
- A Phase 1 trial was initiated for IMVT-1402, with initial data expected in August/September 2023.
Headline financials
Revenue & EPS history
Roivant Sciences · Revenue · Quarterly
$27.4M
Forward guidance
Roivant anticipates several milestones in the coming quarters, including Dermavant's sNDA submission for VTAMA in atopic dermatitis, Immunovant's data readouts for IMVT-1402 and batoclimab trials, Telavant's Phase 2 study of RVT-3101 in Crohn's disease, Priovant's topline results from trials evaluating brepocitinib, Hemavant's data from the RVT-2001 trial, and Kinevant's topline data from the namilumab trial.
Tailwinds
- Dermavant plans to submit its sNDA for VTAMA in atopic dermatitis to the FDA in Q1 2024.
- Immunovant expects IMVT-1402 Phase 1 initial data in August/September 2023 and multiple-ascending dose data in October/November 2023.
- Telavant initiated a Phase 2 dose-ranging study of RVT-3101 in Crohn’s disease with data expected in Q4 2024.
- Priovant plans to announce topline results from the trial evaluating brepocitinib for SLE in Q4 2023.
- Hemavant plans to announce data from the ongoing trial evaluating RVT-2001 for transfusion-dependent anemia in MDS patients in the second half of 2023.
Headwinds
- Top-line results from the Phase 3 thyroid eye disease (TED) program are expected in the second half of calendar year 2025.
- Initial data from period 1 of the Phase 2B trial in chronic inflammatory demyelinating polyneuropathy (CIDP) is expected in the first half of calendar year 2024.
- Initial results from the Phase 2 proof-of-concept trial in GD are expected in the fourth quarter of calendar year 2023.
- Priovant also expects to announce topline results from the Phase 3 trial in dermatomyositis (DM) in calendar year 2025.
- Kinevant plans to report topline data from the ongoing Phase 2 trial of namilumab for the treatment of sarcoidosis in the second half of calendar year 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2023
+3.3%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.4%
Avg return
30 days after
60%
12 / 20 earnings
Positive
+22.1%
Q3 2026
Best reaction
-5.5%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +14.9% | — | — | |
| Q3 2026 | +22.1% | +26.8% | +36.1% | |
| Q2 2026 | +2.6% | -1.6% | -1.8% | |
| Q1 2026 | -2.8% | +3.1% | +19.8% | |
| Q4 2025 | +6.4% | +5.9% | +7.3% | |
| Q4 2024 | -3.4% | +0.0% | -1.5% | |
| Q3 2024 | +4.1% | +6.6% | -5.9% | |
| Q2 2024 | +5.6% | +1.8% | +22.7% | |
| Q1 2024 | -5.2% | -6.1% | -3.5% | |
| Q4 2023 | +9.4% | +7.8% | +28.8% | |
| Q3 2023 | +9.7% | +8.2% | +7.8% | |
| Q2 2023 | +7.4% | -3.1% | +39.9% | |
| Q1 2023 | -5.5% | -15.3% | -15.8% | |
| Q4 2022 | -4.1% | -5.6% | -11.8% | |
| Q3 2021 | +5.1% | -3.2% | -25.4% | |
| Q3 2022 | +5.4% | -3.2% | -25.4% | |
| Q2 2022 | -2.4% | -4.8% | +6.8% | |
| Q2 2021 | -3.8% | -4.8% | +6.8% | |
| Q1 2021 | +0.1% | +0.7% | -38.7% | |
| Q1 2022 | +0.0% | +0.7% | -38.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro